Abstract

Dengue fever, a mosquito- borne viral complaint, is a major public health problem worldwide. It’s aboriginal in numerous tropical and tropical corridor of the world, especially Southeast Asia and the Western Pacific. Annually, roughly 390 million people are at threat for dengue contagion (DENV) infection, including, dengue hemorrhagic fever (DHF) cases and 1000 deaths, substantially children There remains no specific treatment for DENV- infected cases; treatments only give relief of symptoms by close monitoring of vital signs in the critical period between days two and seven of fever, and may include both probative treatment and broad- diapason antiviral agents. Therefore, the development ofanti-DENV agents for the treatment of DENV- infected cases are a high precedence.